Biomea Fusion, Inc. Investing Cash Flow
Biomea Fusion, Inc. (BMEA) reported Investing Cash Flow of $550.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- Biomea Fusion, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $0.00.
- Biomea Fusion, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $550.00K.
- Biomea Fusion, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $0.00.
- Biomea Fusion, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-06-30 was $0.00.
- Biomea Fusion, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$362.00K.
- Biomea Fusion, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$2.22M, a 108.12% decline from fiscal 2022.
- Biomea Fusion, Inc. net cash provided by (used in) investing activities for fiscal 2022 was $27.34M.
- Biomea Fusion, Inc. net cash provided by (used in) investing activities for fiscal 2021 was -$33.35M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $550.00K 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | $550.00K 10-Q · filed 2026-05-11 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | -$82.00K derived: sum of 4 quarters · filed 2026-03-24 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | -$82.00K derived: sum of 3 quarters · filed 2026-03-24 | -$268.00K derived: sum of 4 quarters · filed 2026-03-24 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-05 | -$82.00K derived: sum of 2 quarters · filed 2026-03-24 | -$268.00K derived: sum of 3 quarters · filed 2026-03-24 | -$327.00K derived: sum of 4 quarters · filed 2026-03-24 |
| 2024-12-31 | -$82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$268.00K derived: sum of 2 quarters · filed 2026-03-24 | -$327.00K derived: sum of 3 quarters · filed 2026-03-24 | -$362.00K 10-K · filed 2026-03-24 |
| 2024-09-30 | -$186.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$245.00K derived: sum of 2 quarters · filed 2025-11-04 | -$280.00K 10-Q · filed 2025-11-04 | -$288.00K derived: sum of 4 quarters · filed 2026-03-24 |
| 2024-06-30 | -$59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$94.00K 10-Q · filed 2025-08-05 | -$102.00K derived: sum of 3 quarters · filed 2026-03-24 | -$141.00K derived: sum of 4 quarters · filed 2026-03-24 |
| 2024-03-31 | -$35.00K 10-Q · filed 2025-05-05 | -$43.00K derived: sum of 2 quarters · filed 2026-03-24 | -$82.00K derived: sum of 3 quarters · filed 2026-03-24 | -$499.00K derived: sum of 4 quarters · filed 2026-03-24 |
| 2023-12-31 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$47.00K derived: sum of 2 quarters · filed 2026-03-24 | -$464.00K derived: sum of 3 quarters · filed 2026-03-24 | -$2.22M 10-K · filed 2026-03-24 |
| 2023-09-30 | -$39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | -$456.00K derived: sum of 2 quarters · filed 2024-10-29 | -$2.21M 10-Q · filed 2024-10-29 | -$2.91M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | -$417.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | -$2.17M 10-Q · filed 2024-07-31 | -$2.87M derived: sum of 3 quarters · filed 2025-03-31 | -$2.65M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | -$1.76M 10-Q · filed 2024-05-02 | -$2.46M derived: sum of 2 quarters · filed 2025-03-31 | -$2.23M derived: sum of 3 quarters · filed 2025-03-31 | $5.14M derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | -$701.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$476.00K derived: sum of 2 quarters · filed 2025-03-31 | $6.90M derived: sum of 3 quarters · filed 2025-03-31 | $27.34M 10-K · filed 2025-03-31 |
| 2022-09-30 | $225.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | $7.60M derived: sum of 2 quarters · filed 2023-10-30 | $28.04M 10-Q · filed 2023-10-30 | $32.59M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | $7.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $27.82M 10-Q · filed 2023-07-31 | $32.37M derived: sum of 3 quarters · filed 2024-03-28 | $32.29M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | $20.44M 10-Q · filed 2023-05-02 | $24.99M derived: sum of 2 quarters · filed 2024-03-28 | $24.92M derived: sum of 3 quarters · filed 2024-03-28 | $25.60M derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $4.47M derived: sum of 2 quarters · filed 2024-03-28 | $5.16M derived: sum of 3 quarters · filed 2024-03-28 | -$33.35M 10-K · filed 2024-03-28 |
| 2021-09-30 | -$75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $605.00K derived: sum of 2 quarters · filed 2022-11-07 | -$37.91M 10-Q · filed 2022-11-07 | -$37.94M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $680.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | -$37.83M 10-Q · filed 2022-08-01 | -$37.87M derived: sum of 3 quarters · filed 2023-03-28 | |
| 2021-03-31 | -$38.51M 10-Q · filed 2022-05-16 | -$38.55M derived: sum of 2 quarters · filed 2023-03-28 | ||
| 2020-12-31 | -$39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$51.00K 10-K · filed 2023-03-28 | ||
| 2020-09-30 | -$12.00K 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |